15h
MaxCyte outlines $30M-$32M 2026 revenue outlook as board authorizes $10M share repurchase program
Q1 2026 earnings call: revenue and guidance, Casgevy royalties, DTx/SeQure growth drivers, and $10M buyback—read key takeaways.
We're going to check off day 2 of the BofA Vegas Healthcare Conference. My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team. And I'm excited to be joined by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results